English

Communiqué from Genovis AB (publ) Annual General Meeting May 12, 2022

Report this content

The Annual General Meeting adopted the following resolutions:

  • The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.
  • The Board and the Chief Executive Officer were discharged from liability.
  • The Board shall consist until the next AGM of five ordinary members without deputies.
  • Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist and Steve Jordan.

Magnus Gustafsson was elected new Board member.

Torben Jørgensen was elected Chairperson of the Board.

  • Remuneration will be paid to the Board of Directors in the amount of SEK 150,000 to Board members and SEK 300,000 to the Chairperson of the Board. 
  • The Meeting approved the Board of Directors’ report regarding compensation pursuant to Chapter 8, Section 53 a of the Swedish Companies Act.
  • Remuneration to the auditors will be paid on approved account.  
  • In accordance with the Nomination Committee’s proposal, the Meeting re-elected the accounting firm Öhrlings PricewaterhouseCoopers AB as auditor for the period until the close of the Annual General Meeting 2023.
  • The AGM resolved on the Board of Directors’ proposal for remuneration guidelines for senior executives.
  • A Nomination Committee will be formed with representatives of the four largest shareholders at September 30, 2022.
  • The AGM resolved on the authorization to issue shares with or without preferential rights for existing shareholders. As a result of this resolution, share capital could increase by a maximum of SEK 1,625,000 through the issuance of a maximum of 6,500,000 shares.

Minutes with all resolutions from the meeting will be made available on the company's website:

https://investor.genovis.com/en/corporate-governance/general-meeting/

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: +46 (0)70-276 46 56 fredrik.olsson@genovis.com

Genovis’business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, tel: +46 (0)8-463 83 00.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

Subscribe

Documents & Links